From Concept to Funded: $306,865 Phase I NIH SBIR Award Secured for Breakthrough Nanoemulsion Research
$306,865 Phase I SBIR Award from the National Institutes of Health (NCCIH)
Services Provided: Grant Strategy, Proposal Writing, Administrative Support
Overview
A small biotech R&D firm with patented ultrasonic technology and deep scientific expertise needed more than good science to win federal funding — it needed a compelling, strategically structured proposal that could cut through one of the most competitive grant programs in the country. BW&CO partnered with the firm across the full arc of the engagement, from shaping the funding strategy to delivering a polished, submission-ready application. The result: a $306,865 Phase I Small Business Innovation Research (SBIR) award from the National Institutes of Health's National Center for Complementary and Integrative Health (NCCIH), validating the company's research direction and unlocking the capital needed to advance their work toward commercialization.
The Challenge
The client had developed a genuinely novel technology — a scalable ultrasonic nano-emulsification platform with significant implications for pharmaceutical and nutraceutical applications, including improving the bioavailability of natural therapeutics that have historically been limited by poor water solubility. But translating cutting-edge science into a winning federal grant proposal is a distinct discipline. NIH SBIR competitions are highly selective by design, rewarding not only scientific merit but also the clarity of the commercial pathway, the rigor of the research plan, and the strength of the narrative connecting all three.
The client's internal team had the scientific depth to execute the work but lacked the bandwidth and specialized expertise to develop a proposal that would meet NIH reviewers' expectations. The stakes were high: a Phase I award would not just fund initial research — it would establish credibility with federal funders, open the door to Phase II funding, and accelerate the company's path to market.
Our Approach
BW&CO provided end-to-end support across three core workstreams:
Funding Strategy: Assessed the client's technology, research objectives, and commercial trajectory to identify the right NIH institute and program fit, ultimately targeting NCCIH as the optimal home for a proposal centered on natural therapeutics — ensuring alignment between the science and the funder's priorities before a single word of the proposal was written.
Proposal Writing: Developed and refined all narrative components of the application — including the Specific Aims, Research Strategy, and Commercialization Plan — translating complex scientific concepts into clear, reviewer-ready language that met NIH formatting and content requirements.
Administrative Support: Managed the logistical and compliance dimensions of the submission process, including registration requirements, budget documentation, and deadline coordination, so the client's leadership could remain focused on the science.
Results
BW&CO's support culminated in a successful Phase I SBIR award of $306,865 from NIH/NCCIH (Award Number R43AT013043) — a meaningful milestone for a small company competing in one of the federal government's most rigorous funding programs. The award provides the client with both the capital and the institutional credibility to advance their research on improving the bioavailability of natural therapeutics, build out their proof-of-concept data, and position themselves competitively for Phase II funding.
Beyond the dollar amount, the engagement gave the client a replicable framework for future grant pursuits — a clear sense of how to position their technology for federal audiences and a stronger internal understanding of what it takes to win.